期刊
EXPERT REVIEW OF RESPIRATORY MEDICINE
卷 10, 期 6, 页码 643-654出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17476348.2016.1166960
关键词
Tuberculosis; therapeutics; treatment outcome; biomarkers; humans
资金
- Wellcome Trust (UK) [084323, 104803]
- MRC (UK) [U1175.02.002.00014, FP7-HEALTH-F3-2013-305578, MRC-SHIP-02-2013]
- National Institutes of Health [1U01AI115940-01]
- National Research Foundation of South Africa [96841]
- Wellcome Trust [104803/Z/14/Z] Funding Source: researchfish
- The Francis Crick Institute [10218] Funding Source: researchfish
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI115940] Funding Source: NIH RePORTER
Antibiotic treatment of tuberculosis has a duration of several months. There is significant variability of the host immune response and the pharmacokinetic-pharmacodynamic properties of Mycobacterium tuberculosis sub-populations at the site of disease. A limitation of sputum-based measures of treatment response may be sub-optimal detection and monitoring of Mycobacterium tuberculosis sub-populations. Potential biomarkers and surrogate endpoints should be benchmarked against hard clinical outcomes (failure/relapse/death) and may need tailoring to specific patient populations. Here, we assess the evidence supporting currently utilized and future potential host and pathogen-based models and biomarkers for monitoring treatment response in active and latent tuberculosis. Biomarkers for monitoring treatment response in extrapulmonary, pediatric and drug resistant tuberculosis are research priorities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据